LTS and LIVZON enter into license and collaboration agreement to develop and commercialize ASENAPINE TTS

6.07.2020|Press Releases|

LTS AG and Livzon Pharmaceutical Group Inc. announced today that the companies have entered into an exclusive license and collaboration agreement. LTS grants to LIVZON and its Affiliates an exclusive royalty-bearing, sublicensable right and license to jointly develop with LTS the Asenapine TTS and commercialize the Asenapine TTS for the treatment of schizophrenia in China (including Hong Kong and Macau).

LTS announces the appointment of David Doles as new President and Chief Executive Officer for its US affiliate LTS Corp.

16.12.2019|Company News|

LTS Lohmann Therapie-Systeme AG, the market leader for the development and manufacturing of transdermal therapeutic systems, is very pleased to announce the appointment of Mr. David Doles as the President and Chief Executive Officer for its US affiliate, LTS Lohmann Therapy Systems, Corp. effective 1 January 2020.

LEO Pharma A/S and LTS Lohmann Therapie-Systeme AG initiate first-ever clinical trial of microarray patches for psoriasis treatment

19.03.2019|Press Releases|

LTS Lohmann Therapie-Systeme AG (LTS), a market leader in transdermal therapeutic systems, and LEO Pharma A/S, a global leader in dermatology, today announced that the companies will start the clinical trial of microarray patches for the local intradermal treatment of psoriasis.

Go to Top